BRPI0414594A - derivados de iminoácidos bicìclicos como inibidores de matriz de metaloproteinases - Google Patents

derivados de iminoácidos bicìclicos como inibidores de matriz de metaloproteinases

Info

Publication number
BRPI0414594A
BRPI0414594A BRPI0414594-1A BRPI0414594A BRPI0414594A BR PI0414594 A BRPI0414594 A BR PI0414594A BR PI0414594 A BRPI0414594 A BR PI0414594A BR PI0414594 A BRPI0414594 A BR PI0414594A
Authority
BR
Brazil
Prior art keywords
disease
diseases
acid derivatives
imino acid
ring
Prior art date
Application number
BRPI0414594-1A
Other languages
English (en)
Inventor
Manfred Schudok
Hans Matter
Armin Hofmeister
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of BRPI0414594A publication Critical patent/BRPI0414594A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"DERIVADOS DE IMINOáCIDOS BICìCLICOS COMO INIBIDORES DE MATRIZ DE METALOPROTEINASES". A presente invenção refere-se a compostos da Fórmula (I) Legendas da tabela 1: ring = anel que são apropriados para a preparação de medicamentos para a profilaxia e terapia de doenças, de cujo curso toma parte uma atividade reforçada da matriz de metaloproteinases. Doenças pertencentes a estas são doenças degenerativas das articulações, como por exemplo osteoartroses, espondiloses, lesão dos ligamentos após trauma nas articulações ou após imobilização da articulação depois de maiores lesões no menisco ou na patela ou rupturas dos ligamentos, ou uma doença do tecido conectivo como colagenose, doenças periodontais, distúrbios de cicatrização, ou uma doença crónica do sistema locomotor tal como artrite, aguda ou crónica, artropatias, mialgias, ou perturbações do metabolismo ósseo ou uma ulceração, ateroesclerose, ou estenose ou uma doença inflamatória, ou câncer, formação de metástase tumoral, caquexia, anorexia ou choque séptico.
BRPI0414594-1A 2003-09-27 2004-09-14 derivados de iminoácidos bicìclicos como inibidores de matriz de metaloproteinases BRPI0414594A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10344936A DE10344936A1 (de) 2003-09-27 2003-09-27 Bicyclische Iminosäurederivate als Inhibitoren von Matrix-Metalloproteinasen
PCT/EP2004/010248 WO2005030728A1 (de) 2003-09-27 2004-09-14 Bicyclische iminosäurederivate als inhibitoren von matrix-metalloproteinasen

Publications (1)

Publication Number Publication Date
BRPI0414594A true BRPI0414594A (pt) 2006-11-07

Family

ID=34353126

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0414594-1A BRPI0414594A (pt) 2003-09-27 2004-09-14 derivados de iminoácidos bicìclicos como inibidores de matriz de metaloproteinases

Country Status (24)

Country Link
EP (1) EP1670766B1 (pt)
JP (1) JP4861179B2 (pt)
KR (1) KR20060086367A (pt)
CN (1) CN1856478B (pt)
AR (1) AR046165A1 (pt)
AT (1) ATE550327T1 (pt)
AU (1) AU2004275937A1 (pt)
BR (1) BRPI0414594A (pt)
CA (1) CA2539731A1 (pt)
DE (1) DE10344936A1 (pt)
IL (1) IL174040A0 (pt)
MA (1) MA28075A1 (pt)
ME (1) MEP33008A (pt)
MX (1) MXPA06002927A (pt)
MY (1) MY139830A (pt)
NO (1) NO20061837L (pt)
NZ (1) NZ546158A (pt)
PE (1) PE20050432A1 (pt)
RS (1) RS20060194A (pt)
RU (1) RU2335494C2 (pt)
TW (1) TW200520755A (pt)
UY (1) UY28539A1 (pt)
WO (1) WO2005030728A1 (pt)
ZA (1) ZA200601501B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004031620A1 (de) * 2004-06-30 2006-02-02 Sanofi-Aventis Deutschland Gmbh 4-Trifluormethoxyphenoxybenzol-4`-sulfonsäuren, Verfahren zu ihrer Herstellung und Verwendung in Arzneimitteln
DE102004031850A1 (de) * 2004-06-30 2006-01-26 Sanofi-Aventis Deutschland Gmbh Substituirte Tetrahydroisochinoline als MMP-Inhibitoren, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
DE102005002500A1 (de) 2005-01-19 2006-07-27 Sanofi-Aventis Deutschland Gmbh Tetrahydrofuranderivate als Inhibitoren von Matrix-Metalloproteinasen
DE102005015040A1 (de) * 2005-03-31 2006-10-05 Sanofi-Aventis Deutschland Gmbh Substituierte Tetrahydroisochinoline als MMP-Inhibitoren, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
CA2695504C (en) 2007-08-03 2017-05-30 Nucitec S.A. De C.V. Compositions and methods for treatment and prevention of osteoarthritis

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201303B (pt) * 1990-07-05 1993-03-01 Hoffmann La Roche
US5455258A (en) * 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
FR2701480B1 (fr) * 1993-02-15 1995-05-24 Sanofi Elf Composés à groupe sulfamoyle et amidino, leur procédé de préparation et les compositions pharmaceutiques les contenant.
DK0861236T4 (da) 1995-11-13 2006-12-18 Sanofi Aventis Deutschland Cykliske og heterocykliske N-substituerede alphaiminohydroxam- og carboxylsyrer
SK25699A3 (en) * 1996-08-28 1999-10-08 Procter & Gamble 1,4-heterocyclic metallprotease inhibitors
JP3563411B2 (ja) * 1997-01-23 2004-09-08 エフ・ホフマン−ラ ロシュ アーゲー スルファミド−メタロプロテアーゼ阻害剤
DE10300015A1 (de) * 2003-01-03 2004-07-15 Aventis Pharma Deutschland Gmbh Iminosäurederivate als Inhibitoren von Matrix-Metallproteinasen
DE102004031620A1 (de) * 2004-06-30 2006-02-02 Sanofi-Aventis Deutschland Gmbh 4-Trifluormethoxyphenoxybenzol-4`-sulfonsäuren, Verfahren zu ihrer Herstellung und Verwendung in Arzneimitteln

Also Published As

Publication number Publication date
AR046165A1 (es) 2005-11-30
JP4861179B2 (ja) 2012-01-25
MEP33008A (en) 2010-10-10
NO20061837L (no) 2006-06-01
CN1856478B (zh) 2010-05-26
IL174040A0 (en) 2006-08-01
EP1670766A1 (de) 2006-06-21
PE20050432A1 (es) 2005-07-21
WO2005030728A1 (de) 2005-04-07
RU2006114352A (ru) 2006-08-27
MA28075A1 (fr) 2006-08-01
CA2539731A1 (en) 2005-04-07
UY28539A1 (es) 2005-04-29
JP2007506690A (ja) 2007-03-22
TW200520755A (en) 2005-07-01
ZA200601501B (en) 2007-04-25
AU2004275937A1 (en) 2005-04-07
KR20060086367A (ko) 2006-07-31
RS20060194A (en) 2008-08-07
NZ546158A (en) 2008-11-28
EP1670766B1 (de) 2012-03-21
DE10344936A1 (de) 2005-04-21
MXPA06002927A (es) 2006-06-14
MY139830A (en) 2009-10-30
CN1856478A (zh) 2006-11-01
RU2335494C2 (ru) 2008-10-10
ATE550327T1 (de) 2012-04-15

Similar Documents

Publication Publication Date Title
BRPI0407919A (pt) pirrolopirimidinas espiro-substituìdas
Zeng et al. Icariin inhibits MMP‑1, MMP‑3 and MMP‑13 expression through MAPK pathways in IL‑1β‑stimulated SW1353 chondrosarcoma cells
BRPI0413616B1 (pt) 2,4-pirimidinadiaminas, seus usos, e composição farmacêutica
WO2018226732A1 (en) Multibiotic agents and methods of using the same
BR0212226A (pt) Pirrolo pirimidinas como agentes para inibição de cisteìna proteases
ATE361300T1 (de) Derivate von heteroarylnitrilverbindungen
BRPI0509340A (pt) formulação compreendendo inibidores de histona desacetilase
BRPI0514448A (pt) derivados do ácido bifenil-oxiacético para uso no tratamento de doenças respiratórias
BR0010555A (pt) Inibidores de neuraminidases
NO20044744L (no) Karbaminsyreforbindelser omfattende et piperazinledd som HDASinbibitorer
BRPI0413490A (pt) novos compostos
CL2004000848A1 (es) Compuestos derivados de fenacil-2-hidroxi-3-diaminoalcanos, inhibidores de la enzima betasecretasa, utiles para preparar un medicamento para tratar alzheimer, sindrome de down, hemorragia cerebral hereditaria con amiloidosis de tipo holandes, y otras
ITMI20031311A1 (it) Formulazioni per il trattamento di disturbi artrosici.
BR9815596A (pt) Composto, composição farmacêutica, método de tratamento de doenças inflamatórias e método de tratamento de condição ou doença mediada por mmps e/ou tnf e/ou agrecanase
BR112013030874B8 (pt) Uso de uma theta-defensina ou análogo da mesma para tratar uma condição inflamatória crônica
BRPI0414594A (pt) derivados de iminoácidos bicìclicos como inibidores de matriz de metaloproteinases
BR9908215A (pt) Derivados de ácidos hidroxâmico e carboxìlico
BR0115306A (pt) Composto, prodroga, composição farmacêutica, agente para diminuir androgênio, método para a produção de um composto, e, sal diastereomérico
PT1124841E (pt) Fenil-alcenoil-guanidinas processo para a sua preparacao sua utilizacao como medicamentos ou meios de diagnostico bem como composicao farmaceutica que as contem
SV2006002192A (es) Amidas del acido 5 y 6-aminoalquil indol-2-carboxilico 3-sustituidas y analogos relacionados como inhibidores de la caseina cinasa ie
BRPI0606493A2 (pt) derivados de tetrahidrofurano para uso como inibidores das metaloproteinases da matriz
BR0308088A (pt) ácidos alfa-iminocarboxìlicos substituìdos com n, cìclicos, para a inibição seletiva de colagenase
SV1997000037A (es) Inhibisor de matrices de metaloproteasas mediante compuestos sustituidos de fenalquilo,
MY128242A (en) Hallogenated aminobenzophenones and aminobenzoylpyridines as inhibitors of il-1 and tnf
CL2004000810A1 (es) Compuesto derivado de acido hidroxamico de formula definida; composicion farmaceutica que comprende al compuesto y uso del compuesto para preparar medicamentos utiles para tratar trastornos hiperproliferativos.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.